These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11923792)

  • 21. Angiotensin converting enzyme (ACE) inhibitors and heart failure. The consequences of underprescribing.
    Andersson F; Cline C; Rydén-Bergsten T; Erhardt L
    Pharmacoeconomics; 1999 Jun; 15(6):535-50. PubMed ID: 10538327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced costs with bisoprolol treatment for heart failure: an economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II).
    Eur Heart J; 2001 Jun; 22(12):1021-31. PubMed ID: 11428837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimating the cost effectiveness of ramipril used for specific clinical indications: comparing the outcomes in four clinical trials with a common economic model.
    Grover SA; Coupal L; Lowensteyn I
    Am J Cardiovasc Drugs; 2007; 7(6):441-8. PubMed ID: 18076211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cost-effective way forward for the management of the patient with heart failure.
    Giles T
    Cardiology; 1996; 87 Suppl 1():33-9. PubMed ID: 8681320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada.
    Levy AR; Briggs AH; Demers C; O'Brien BJ
    Am Heart J; 2001 Sep; 142(3):537-43. PubMed ID: 11526370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.
    Teng TK; Tromp J; Tay WT; Anand I; Ouwerkerk W; Chopra V; Wander GS; Yap JJ; MacDonald MR; Xu CF; Chia YM; Shimizu W; ; Richards AM; Voors A; Lam CS
    Lancet Glob Health; 2018 Sep; 6(9):e1008-e1018. PubMed ID: 30103979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost of medical services in older patients with heart failure: those receiving enhanced monitoring using a computer-based telephonic monitoring system compared with those in usual care: the Heart Failure Home Care trial.
    Soran OZ; Feldman AM; Piña IL; Lamas GA; Kelsey SF; Selzer F; Pilotte J; Lave JR
    J Card Fail; 2010 Nov; 16(11):859-66. PubMed ID: 21055649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost of heart failure to the healthcare system.
    Mackowiak J
    Am J Manag Care; 1998 Jun; 4(6 Suppl):S338-42. PubMed ID: 10184926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Digoxin and clinical outcomes in systolic heart failure patients on contemporary background heart failure therapy.
    Dhaliwal AS; Bredikis A; Habib G; Carabello BA; Ramasubbu K; Bozkurt B
    Am J Cardiol; 2008 Nov; 102(10):1356-60. PubMed ID: 18993155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence.
    Dulin BR; Krum H
    Curr Opin Cardiol; 2006 Jul; 21(4):393-9. PubMed ID: 16755210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic burden of heart failure: a summary of recent literature.
    Lee WC; Chavez YE; Baker T; Luce BR
    Heart Lung; 2004; 33(6):362-71. PubMed ID: 15597290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group.
    Sculpher MJ; Poole L; Cleland J; Drummond M; Armstrong PW; Horowitz JD; Massie BM; Poole-Wilson PA; Ryden L
    Eur J Heart Fail; 2000 Dec; 2(4):447-54. PubMed ID: 11113723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is multidisciplinary care of heart failure cost-beneficial when combined with optimal medical care?
    Ledwidge M; Barry M; Cahill J; Ryan E; Maurer B; Ryder M; Travers B; Timmons L; McDonald K
    Eur J Heart Fail; 2003 Jun; 5(3):381-9. PubMed ID: 12798838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Heart failure - up to date].
    Müller-Edenborn B; Eriksson U
    Praxis (Bern 1994); 2013 Aug; 102(17):1053-60. PubMed ID: 23965718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pharmacoeconomics of ACE inhibitors in chronic heart failure.
    McMurray J; Davie A
    Pharmacoeconomics; 1996 Mar; 9(3):188-97. PubMed ID: 10160096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosis and management of heart failure in the long-term care setting.
    Gaulden L
    Director; 2003; 11(4):177-81. PubMed ID: 14608703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prophylactic pacemaker use to allow beta-blocker therapy in patients with chronic heart failure with bradycardia.
    Stecker EC; Fendrick AM; Knight BP; Aaronson KD
    Am Heart J; 2006 Apr; 151(4):820-8. PubMed ID: 16569541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of beta-blocker treatment in heart failure.
    Gilbert EM
    Rev Cardiovasc Med; 2002; 3 Suppl 3():S42-7. PubMed ID: 12447161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis.
    Smith DG; Cerulli A; Frech FH
    Clin Ther; 2005 Jun; 27(6):951-9. PubMed ID: 16117995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The cost-effectiveness of losartan versus captopril in patients with symptomatic heart failure.
    Dasbach EJ; Rich MW; Segal R; Gerth WC; Carides GW; Cook JR; Murray JF; Snavely DB; Pitt B
    Cardiology; 1999; 91(3):189-94. PubMed ID: 10516413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.